Journal Article

Prevalence and clinical implications of persistent or exertional cardiopulmonary symptoms following SARS-CoV-2 infection in 3597 collegiate athletes: a study from the Outcomes Registry for Cardiac Conditions in Athletes (ORCCA)

Taylor, Kenneth S, Chill, Nicholas, Sakamoto, Takamasa, Haylett, Julie, Soslow, Jonathon H, Bohon, Tiffany, Beaver, Timothy, Monseau, Aaron J, Riveros, Diego, Carnahan, Sean, Priestman, Diana, Stovak, Mark, Kussman, Andrea, Magee, Lawrence M, Robinson, James B, Davitt, Kaitlin, Drezner, Jonathan A, Kraus, William E, Joyce, Donald, Edenfield, Katherine M, Taylor, Herman A, Harmon, Kimberly G, Lowery, Maureen, Cook, Laura E, Tarsici, Andrei, Winningham, Jennifer, Huston, Lindsay, Duffaut, Calvin, Moulson, Nathaniel, Schnebel, Brock, Howard, Julia, Goldberger, Jeffrey, Charters, Samantha, DeZenzo, Katelyn, Myerburg, Robert J, Shah, Ankit B, Maurice, Annabelle DeSt, Berkstresser, Brant, Mytyk, Greg, Dimitris, Courtney, Reifsteck, Fred, Costa, Amy, Husaini, Mustafa, Nattiv, Aurelia, Halseth, Heather, Magnuson, Marja-Liisa, Organ, Brooke E, Boyington, Elizabeth, Rink, Lawrence D, Austin, Andrea, Kirk, Michele, Lothian, Dylan, Lukjanczuk, Andrew, McKinley, Grant, Emery, Michael S, Hare, Joshua, Pendergast, Meredith, Klein, Christian, Leiszler, Matthew, Amaradio, Chloe, Kuscher, Yumi, Karlson, Kristine, Landreth, C

2022

Overview

ObjectiveTo assess the prevalence and clinical implications of persistent or exertional cardiopulmonary symptoms in young competitive athletes following SARS-CoV-2 infection.MethodsThis observational cohort study from the Outcomes Registry for Cardiac Conditions in Athletes included 3597 US collegiate athletes after SARS-CoV-2 infection. Clinical characteristics, advanced diagnostic testing and SARS-CoV-2-associated sequelae were compared between athletes with persistent symptoms >3 weeks, exertional symptoms on return to exercise and those without persistent or exertional symptoms.ResultsAmong 3597 athletes (mean age 20 years (SD, 1 year), 34% female), data on persistent and exertional symptoms were reported in 3529 and 3393 athletes, respectively. Persistent symptoms >3 weeks were present in 44/3529 (1.2%) athletes with 2/3529 (0.06%) reporting symptoms >12 weeks. Exertional cardiopulmonary symptoms were present in 137/3393 (4.0%) athletes. Clinical evaluation and diagnostic testing led to the diagnosis of SARS-CoV-2-associated sequelae in 12/137 (8.8%) athletes with exertional symptoms (five cardiac involvement, two pneumonia, two inappropriate sinus tachycardia, two postural orthostatic tachycardia syndrome and one pleural effusion). No SARS-CoV-2-associated sequelae were identified in athletes with isolated persistent symptoms. Of athletes with chest pain on return to exercise who underwent cardiac MRI (CMR), 5/24 (20.8%) had probable or definite cardiac involvement. In contrast, no athlete with exertional symptoms without chest pain who underwent CMR (0/20) was diagnosed with probable or definite SARS-CoV-2 cardiac involvement.ConclusionCollegiate athletes with SARS-CoV-2 infection have a low prevalence of persistent or exertional symptoms on return to exercise. Exertional cardiopulmonary symptoms, specifically chest pain, warrant a comprehensive evaluation.

• Publisher: BMJ Publishing Group Ltd and British Association of Sport and Exercise Medicine,BMJ Publishing Group LTD,BMJ Publishing Group
• Subject: Asthma / Asymptomatic / Body mass index / Coronaviruses / COVID-19 / Diagnostic tests / Fingers & toes / Infections / Laboratories / Original Research / Patients / Pre-existing conditions / Severe acute respiratory syndrome coronavirus 2 / sports / Student athletes